Floatz logo

Idov-Safetm

Neoplasms

Cancer Institute and Hospital, Chinese Academy of Medical SciencesEarly Phase 1Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
65/ 100

Competitive context

118 Active assets in the Neoplasms cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
Feladilimab
GlaxoSmithKline
Phase 2BB
Carboplatin
Bristol-Myers Squibb
Phase 3BB
Cetuximab
Mirati Therapeutics Inc.
Phase 4B
PREDNISONE TABLETS
The First Affiliated Hospital of Soochow University
Phase 3B

View all 50 →

Same molecule, other indications

Idov-Safetm is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
Advanced Solid TumorsDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →